Company Overview
KAIROS PHARMA, LTD.
KAPARevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
100M
2025 FY
Net Income
-5M
2025 FY
Shares Outstanding
18M
2025 FY
EPS
-0.3USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1962011
Exchange
NYSE
Location
US